We will open our meeting for our study on pharmacare.
We're very privileged today to have some testimony from the Netherlands and Sweden.
We very much appreciate your attending our meeting in Canada. I'm not sure what time of day it is there, but thank you very much for doing this. We're studying a national pharmacare program, and we're trying to avoid any pitfalls in our study if we can. I'm sure your testimony will help us.
First of all, we have Sofia Wallström, director general of the Dental and Pharmaceutical Benefits Agency of Sweden. We also have Aldo Golja, senior policy advisor on pricing and reimbursement of pharmaceuticals at the Dutch ministry of health.
I am going to start the questioning with Mr. Kang.